Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Oisín Kavanagh; Anne Marie Healy; Francis Dayton; Shane Robinson; Niall J. O'Reilly; Brian Mahoney; Aisling Arthur; Gavin Walker; John P. Farragher

doi:10.1016/j.mehy.2020.110110

Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Oisín Kavanagh
, Anne Marie Healy
, Francis Dayton
, Shane Robinson
, Niall J. O'Reilly
, Brian Mahoney
, Aisling Arthur
, Gavin Walker
, John P. Farragher

The Science Foundation Ireland Research Centre for Pharmaceuticals
University of Limerick
Trinity College Dublin
Janssen Sciences Ireland UC
South East Technological University

Research output: Contribution to journal › Letter › peer-review

Abstract

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.

Original language	English
Article number	110110
Journal	Medical Hypotheses
Volume	143
DOIs	https://doi.org/10.1016/j.mehy.2020.110110
Publication status	Published - Oct 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.mehy.2020.110110

Cite this

@article{d5d29a9b19a84a52a8978f1ad2e98cbe,

title = "Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19",

abstract = "Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.",

author = "Ois{\'i}n Kavanagh and \{Marie Healy\}, Anne and Francis Dayton and Shane Robinson and O'Reilly, \{Niall J.\} and Brian Mahoney and Aisling Arthur and Gavin Walker and Farragher, \{John P.\}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = oct,

doi = "10.1016/j.mehy.2020.110110",

language = "English",

volume = "143",

journal = "Medical Hypotheses",

issn = "0306-9877",

}

TY - JOUR

T1 - Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

AU - Kavanagh, Oisín

AU - Marie Healy, Anne

AU - Dayton, Francis

AU - Robinson, Shane

AU - O'Reilly, Niall J.

AU - Mahoney, Brian

AU - Arthur, Aisling

AU - Walker, Gavin

AU - Farragher, John P.

PY - 2020/10

Y1 - 2020/10

N2 - Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.

AB - Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.

UR - https://www.scopus.com/pages/publications/85088049991

U2 - 10.1016/j.mehy.2020.110110

DO - 10.1016/j.mehy.2020.110110

M3 - Letter

C2 - 33017904

AN - SCOPUS:85088049991

SN - 0306-9877

VL - 143

JO - Medical Hypotheses

JF - Medical Hypotheses

M1 - 110110

ER -

Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this